EGFR and non-small cell lung carcinoma: Our analysis of the subset of studies providing whole‐exome sequencing data on large numbers of patients with NSCLC shows that, overall, SMARCA4 mutations are generally associated with poor prognosis regardless of therapy; ARID1A mutations are typically associated with better prognosis after ICI therapy; ARD1A/EGFR‐comutations are not susceptible to treatment with EGFR TKIs; and pBAF complex mutations, especially of PBRM1, are strongly associated with poor outcomes after ICI therapy.